Intellipharmaceutics & Par Pharmaceutical Expand Development & Commercialization Agreement
Intellipharmaceutics International Inc. recently announced that they have added the development and commercialization of additional strengths of generic Focalin XR (dexmethylphenidate hydrochloride) for the
Under the terms of the expanded agreement, Intellipharmaceutics will receive an immediate cash payment from Par and will continue to receive a share of profits from future sales. According to Wolters Kluwer Health,
Intellipharmaceutics and Par are parties to a settlement of their earlier
“We are extremely pleased with the expansion of the agreement we currently have in place with Par for the development and commercialization of generic Focalin XR,” commented Dr. Isa Odidi, CEO of Intellipharmaceutics. “Today’s announcement adds further credibility to the quality of our work and the growth of our company.”
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development, and manufacture of novel or generic controlled-release and targeted-release oral solid dosage drugs. The company’s patented Hypermatrix technology is a unique and validated multidimensional controlled-release drug delivery platform that can be applied to the efficient development of a wide range of existing and new pharmaceuticals.
Total Page Views: 988
